Immunotherapy, increasing efficacy
Immunotherapy, increasing efficacy
Monoclonal antibodies have changed the evolution of many diseases, in particular in multiple sclerosis, an inflammation of the central nervous system that causes myelin to degenerate, modifying the functioning of neurological impulses to the brain. Immunotherapy can make use of various drugs, old and new. One of the most recent is Ocrealizumab which is effective in standard and more severe forms. It is a humanized monoclonal antibody designed to target CD20–positive B cells, one of the major cells responsible for myelin damage.
Monoclonal antibodies have changed the evolution of many diseases, in particular in multiple sclerosis, an inflammation of the central nervous system that causes myelin to degenerate, modifying the functioning of neurological impulses to the brain. Immunotherapy can make use of various drugs, old and new. One of the most recent is Ocrealizumab which is effective in standard and more severe forms. It is a humanized monoclonal antibody designed to target CD20–positive B cells, one of the major cells responsible for myelin damage.
Metastatic Melanoma: 5-year survival rates may soon reach 60%
en
Prof. Claus Garbe
Sclerosi Multipla: vecchi e nuovi anticorpi monoclonali a confronto
it
Prof. Giancarlo Comi
Immunotherapy in advanced squamous cell carcinoma
en
Prof. Michael R. Migden
Immunotherapy: useful information from lung cancer treatment
en
Prof. Rolf Stahel
Efficacy and fields of application of the CAR-T cell therapy
en
Prof. Davide Rossi
CAR-T cells vs bispecific monoclonal antibodies in lymphoma therapy
it
Prof. Franco Cavalli
Immunoterapia efficace nel carcinoma spinocellulare
it
Prof. Iris Zalaudek
Subtypes of sarcoma responsive to immunotherapy
en
Prof. Robert Maki